Head-To-Head Comparison: Lotus Pharmaceuticals (OTCMKTS:LTUS) & AbbVie (NYSE:ABBV)

0
53
Head-To-Head Comparison: Lotus Pharmaceuticals (OTCMKTS:LTUS) & AbbVie (NYSE:ABBV)



Lotus Pharmaceuticals (OTCMKTS:LTUS – Get Rating) and AbbVie (NYSE:ABBV – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Lotus Pharmaceuticals and AbbVie, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lotus Pharmaceuticals 0 0 0 0 N/A
AbbVie 0 4 12 0 2.75

AbbVie has a consensus target price of $157.73, suggesting a potential upside of 7.39%. Given AbbVie’s higher possible upside, analysts plainly believe AbbVie is more favorable than Lotus Pharmaceuticals.

Earnings and Valuation

This table compares Lotus Pharmaceuticals and AbbVie’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lotus Pharmaceuticals N/A N/A N/A N/A N/A
AbbVie $56.20 billion 4.62 $11.54 billion $6.97 21.07

AbbVie has higher revenue and earnings than Lotus Pharmaceuticals.

Institutional & Insider Ownership

65.6% of AbbVie shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Lotus Pharmaceuticals and AbbVie’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lotus Pharmaceuticals N/A N/A N/A
AbbVie 20.54% 164.05% 15.29%

Volatility & Risk

Lotus Pharmaceuticals has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Summary

AbbVie beats Lotus Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

About Lotus Pharmaceuticals (Get Rating)

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People’s Republic of China. The company is based in Nashville, Tennessee.

About AbbVie (Get Rating)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet’s diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.



Receive News & Ratings for Lotus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lotus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link